These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25044757)

  • 1. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
    Vallespí MG; Pimentel G; Cabrales-Rico A; Garza J; Oliva B; Mendoza O; Gomez Y; Basaco T; Sánchez I; Calderón C; Rodriguez JC; Markelova MR; Fichtner I; Astrada S; Bollati-Fogolín M; Garay HE; Reyes O
    J Pept Sci; 2014 Nov; 20(11):850-9. PubMed ID: 25044757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552.
    Astrada S; Gomez Y; Barrera E; Obal G; Pritsch O; Pantano S; Vallespí MG; Bollati-Fogolín M
    J Pept Sci; 2016 Nov; 22(11-12):711-722. PubMed ID: 27933724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity.
    Astrada S; Fernández Massó JR; Vallespí MG; Bollati-Fogolín M
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29601540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models.
    Gomez Rodriguez Y; Oliva Arguelles B; Riera-Romo M; Fernandez-De-Cossio J; Garay HE; Fernandez Masso J; Guerra Vallespi M
    Mol Biol Rep; 2022 Apr; 49(4):3197-3212. PubMed ID: 35094208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1.
    Daghero H; Fernández Massó JR; Astrada S; Guerra Vallespí M; Bollati-Fogolín M
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552.
    Vallespi MG; Rodriguez JC; Seoane LC; Alvarez P; Santana H; Garay H; Cabrera IA; Espinosa JT; Reyes O
    Res Vet Sci; 2017 Oct; 114():502-510. PubMed ID: 28987957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic Study to Survey the CIGB-552 Antitumor Effect.
    Rodríguez-Ulloa A; Gil J; Ramos Y; Hernández-Álvarez L; Flores L; Oliva B; García D; Sánchez-Puente A; Musacchio-Lasa A; Fernández-de-Cossio J; Padrón G; González López LJ; Besada V; Guerra-Vallespí M
    Biomed Res Int; 2015; 2015():124082. PubMed ID: 26576414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
    Vallespi MG; Mestre B; Marrero MA; Uranga R; Rey D; Lugiollo M; Betancourt M; Silva K; Corrales D; Lamadrid Y; Rodriguez Y; Maceo A; Chaviano PP; Lemos G; Cabrales A; Freyre FM; Santana H; Garay HE; Oliva B; Fernandez JR
    Int J Cancer; 2021 Sep; 149(6):1313-1321. PubMed ID: 34019700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
    Bequet-Romero M; Morera Y; Ayala-Ávila M; Ancizar J; Soria Y; Blanco A; Suárez-Alba J; Gavilondo JV
    Vaccine; 2012 Feb; 30(10):1790-9. PubMed ID: 22240345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy.
    Oliva Arguelles B; Riera-Romo M; Guerra Vallespi M
    Br J Pharmacol; 2020 Aug; 177(16):3625-3634. PubMed ID: 32436254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
    Perera Y; Farina HG; Hernández I; Mendoza O; Serrano JM; Reyes O; Gómez DE; Gómez RE; Acevedo BE; Alonso DF; Perea SE
    Int J Cancer; 2008 Jan; 122(1):57-62. PubMed ID: 17847034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells.
    Núñez de Villavicencio-Díaz T; Ramos Gómez Y; Oliva Argüelles B; Fernández Masso JR; Rodríguez-Ulloa A; Cruz García Y; Guirola-Cruz O; Perez-Riverol Y; Javier González L; Tiscornia I; Victoria S; Bollati-Fogolín M; Besada Pérez V; Guerra Vallespi M
    J Proteomics; 2015 Aug; 126():163-71. PubMed ID: 26013411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced serum proteolysis resistance of cell-penetrating peptides.
    Fominaya J; Bravo J; Decaudin D; Brossa JY; Nemati F; Rebollo A
    Ther Deliv; 2015 Feb; 6(2):139-47. PubMed ID: 25690083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.
    Garay H; Espinosa LA; Perera Y; Sánchez A; Diago D; Perea SE; Besada V; Reyes O; González LJ
    J Pept Sci; 2018 Jun; 24(6):e3081. PubMed ID: 29676523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
    Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
    Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-dimensional poly(L-lysine)-block-poly(L-threonine) assemblies exhibit potent anticancer activity by enhancing membranolysis.
    Chen YF; Shiau AL; Chang SJ; Fan NS; Wang CT; Wu CL; Jan JS
    Acta Biomater; 2017 Jun; 55():283-295. PubMed ID: 28412555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD.
    Liu R; Xi L; Luo D; Ma X; Yang W; Xi Y; Wang H; Qian M; Fan L; Xia X; Li K; Wang D; Zhou J; Meng L; Wang S; Ma D
    J Control Release; 2012 Aug; 161(3):893-902. PubMed ID: 22580115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
    Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
    Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells.
    Fernández Massó JR; Oliva Argüelles B; Tejeda Y; Astrada S; Garay H; Reyes O; Delgado-Roche L; Bollati-Fogolín M; Vallespí MG
    J Amino Acids; 2013; 2013():251398. PubMed ID: 23401744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
    Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
    Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.